38th week of 2009 patent applcation highlights part 31 |
Patent application number | Title | Published |
20090232833 | POLYALKYLENE OXIDES HAVING HINDERED ESTER-BASED BIODEGRADABLE LINKERS - The present invention provides polymeric delivery systems including hindered ester moieties. Methods of making the polymeric delivery systems and methods of treating mammals using the same are also disclosed. | 2009-09-17 |
20090232834 | Methods and Agents to Treat Autoimmune Diseases - A therapeutic method for preventing, suppressing, or treating an autoimmune disease is described. This method involves administering to a patient suffering from an autoimmune disease an effective amount of a composition containing an allogeneic or autologous leucocyte cell population derived from a healthy donor. The composition is administered by subcutaneous injection and induces an immunological response in recipient patients sufficient to reduce incidence, prevalence, frequency, or severity of the autoimmune disease. | 2009-09-17 |
20090232835 | Composition for delivery of hematopoietic growth factor - A hematopoietic growth factor delivery composition includes a hematopoietic growth factor, a liquid vehicle, a first biocompatible polymer and a second biocompatible polymer. The composition exhibits reverse-thermal viscosity behavior, due to interaction between the first biocompatible polymer and the liquid vehicle. The second biocompatible polymer helps to protect the first biocompatible polymer from being dissolved in vivo following administration to a host. | 2009-09-17 |
20090232836 | Vaccine Compositions for Inducing Immune Responses Against Components of Drusen - Disclosed are compositions and methods for treating or preventing the formation of drusen in a patient in need thereof. The compositions include an effective amount of at least one polypeptide present in drusen, or an immunogenic fragment or variant thereof that induces an immune response against the polypeptide, together with a pharmaceutical carrier, excipient, or diluent. The compositions are suitable as vaccines for treating or preventing drusen and diseases associated with drusen. | 2009-09-17 |
20090232837 | ANTI TUMORAL IMMUNOGENIC PEPTIDES AND VACCINE THEREOF - The invention relates to novel, Frizzled-like, immunogenic peptides, useful for the stimulation of an immune response against various cancer types, particularly colon rectal carcinoma. | 2009-09-17 |
20090232838 | Ligands of melanocortin receptors - The present invention is directed to a compound according to formula, (R | 2009-09-17 |
20090232839 | MELANOMA ASSOCIATED PEPTIDE ANALOGUES AND VACCINES AGAINST MELANOMA - The present invention is concerned with cancer treatment and diagnosis, especially with melanoma associated peptide analogues with improved immunogenicity, epitopes thereof, vaccines against melanoma, tumor infiltrating T lymphocytes recognizing the antigen and diagnostics for the detection of melanoma and for the monitoring of vaccination. The peptides according to the invention can be exploited to elicit native epitope-reactive Cm. Usage of the peptides with improved immunogenicity may contribute to the development of CTL-epitope based vaccines in viral disease and cancer. | 2009-09-17 |
20090232840 | VACCINES AGAINST ESCHERICHIA COLI O157 INFECTION - This invention relates to conjugates of the O-specific polysaccharide of | 2009-09-17 |
20090232841 | Optimzed vaccines to provide protection against ebola and other viruses - The invention is related to a nucleic acid molecule comprising a polynucleotide encoding a modified filovirus glycoprotein (GP) having at least one amino acid change located in a relatively conserved region of said GP that decreases in vitro cytotoxicity and retains immunogenicity when compared to in vitro cytotoxicity and immunogenicity of a wild type filovirus GP, and related modified filovirus GPs, plasmid DNAs, recombinant viruses, adenoviruses, pharmaceutical compositions, vaccine compositions, antibodies that are specifically reactive with the modified filovirus GPs, and related methods of making and using the same. | 2009-09-17 |
20090232842 | HPV Vaccine Comprising Peptides From Host Cell Proteins - The present invention relates to a human papillomavirus (HPV) vaccine that comprises peptides from host cell proteins and more particularly, a vaccine that is directed against cancers that are associated with HPV infections, such as cervical cancer, head and neck cancer and skin cancers. The peptides comprise fragments of host cell proteins that have been targeted for degradation by HPV proteins, such as E6 and E7 and are presented on the surface of HPV infected cells in relatively large amounts. These peptides can be recognised by CTL and elicit an immune response, and are therefore ideal tumour-specific markers. The invention also relates to novel peptide: peptide complexes such as peptide/HLA complexes and their use in a tumour-specific vaccine. | 2009-09-17 |
20090232843 | Identifying and predicting influenza variants and uses thereof - The instant invention provides methods for determining, predicting and characterizing the genetic variability of viruses, in particular, influenza. Accordingly, the invention provides methods for identifying virulent pathogens, genetic mutations within pathogens that are relevant to animal health, and methods and compositions for prophylactic or therapeutic intervention against such pathogens. | 2009-09-17 |
20090232844 | IMMUNOPOTENTIATING COMPOUNDS - The invention provides novel compositions comprising Imidazopyridine compounds. Also provided are methods of administering the compositions in an effective amount to enhance the immune response of a subject. Further provided are novel compositions and methods of administering the compositions in combination with (an)other agent(s). | 2009-09-17 |
20090232845 | Newcastle disease virus monoclonal antibodies - Anti-peptide monoclonal antibodies (MAb's) specific for Exotic Newcastle Disease (END) are used for rapid diagnostic identification between poultry infected with vaccine strains of NDV (LaSota/B1) and END virus (ENDV). Exotic Newcastle Disease is a contagious and fatal viral disease of birds and poultry. The present invention provides for diagnostic detection of ENDV in commercial poultry. | 2009-09-17 |
20090232846 | Pestivirus mutant for use in a vaccine - The present invention comprises new pestivirus mutants, characterized in that the mutants are based on a cp strain of the virus wherein part of the gene sequence encoding the Npro region is deleted, except that the deleted part does not encompass the coding sequence for the N-terminal twelve amino acids of the Npro protein. Preferably the pestivirus is the Bovine Viral Diarrhea Virus (BVDV). It was found that a mutant according to the invention is a safe and efficient vaccine candidate. | 2009-09-17 |
20090232847 | Immunogenic compositions - The present invention relates to methods and compositions useful in the treatment and prevention of Hepatitis C virus (HCV) infections and the symptoms and diseases associated therewith. In particular the present invention relates to DNA vaccines that encode the HCV Core protein and a polynucleotide sequence that encodes at least one other HCV protein, wherein the vaccine causes expression of the proteins within the same cell and the sequence of the polynucleotide sequence encoding the core protein has been mutated or positioned relative to the polynucleotide sequence encoding the at least one other HCV protein such that the negative effect of expression of the Core protein upon the expression of the said at least one other HCV protein is reduced. | 2009-09-17 |
20090232848 | METHODS FOR CULTIVATING LAWSONIA INTRACELLULARIS - This invention relates to methods for cultivating | 2009-09-17 |
20090232849 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER - Compositions and a method for sensitizing a cancer for treatment by cytotoxic therapy is disclosed. The method includes the step of administering to the cancerous tissue or cells a pharmaceutical composition containing a | 2009-09-17 |
20090232850 | THERAPEUTIC TREATMENTS USING BOTULINUM NEUROTOXIN - Methods for treating a coronary risk factor (such as hypertension, diabetes, hyperlipidemia and obesity) and/or a respiratory disorder (such as asthma, chronic obstructive pulmonary disease and bronchitis) and/or arthritis by local administration of a botulinum neurotoxin to at least one of a head, neck or shoulder location (for example, by subdermal, subcutaneous or intramuscular administration of the botulinum neurotoxin) of a patient with a coronary risk factor, respiratory disorder or arthritis. | 2009-09-17 |
20090232851 | SIMULTANEOUS, SEPARATE OR SEQUENTIAL THERAPEUTIC USE OF AT LEAST ONE BOTULINUM NEUROTOXIN AND OF AT LEAST ONE OPIATE DERIVATIVE - The present invention relates to a composition comprising: at least one botulinum neurotoxin, and at least one opiate derivative or its salt. The invention also relates to a product comprising at least one botulinum neurotoxin and at least one opiate derivative or its salt, as a combination product for simultaneous, separate or sequential therapeutic use in the treatment or prevention of pain and of neuromuscular disorders. | 2009-09-17 |
20090232852 | USE OF OUTER MEMBRANE PROTEIN A (OMPA) IN TREATMENT/PREVENTION/DIAGNOSIS OF INFECTIONS CAUSED BY KLEBSIELLA PNEUMONIAE AND OTHER GRAM-NEGATIVE BACTERIA - The present invention provides a method for the treatment and/or prevention of bacterial infection caused by | 2009-09-17 |
20090232853 | TREATMENT OF LAMINITIS - The present invention provides a composition comprising one or more of a matrix metalloprotease inhibitor, a de-carboxylase inhibitor, a fructanase enzyme and/or a flavonoid for use in the prevention of laminitis | 2009-09-17 |
20090232854 | USES OF BISPECIFIC ANTIBODY COATED DENDRITIC CELLS PULSED WITH ANTIGENS AND GM-CSF IN IMMUNE REGULATION - GM-CSF administered before immunization exerted a sustained suppressive effect against the induction of myasthenia gravis (MG). This suppression was associated with lowered serum autoantibody levels, reduced T cell proliferative responses to AChR, and an expansion in the population of FoxP3+ regulatory T cells. Manipulating DCs to expand regulatory T cells is useful for the control of autoimmune diseases such as myasthenia gravis MG. | 2009-09-17 |
20090232855 | Percutaneous controlled releasing material using nano-sized polymer particles and external application agent containing the same - A percutaneous releasing material and agent having characteristics that include a high stability of an active agent in the formulation, a high topical absorption rate, decreased irritation on the skin, and an increased tactile comfort. The percutaneous releasing material incorporates an external application agent composition that is prepared by using nanometer-sized polymer particles, i.e., particles having a size or diameter between approximately 1 nm and approximately 500 nm, and more preferably having a size between about 30 nm and about 150 nm. Further, the percutaneous releasing material and agent according to the present invention incorporate polymer particles that preferably contain a physiologically active agent that more readily penetrates through the stratum corneum to the upper layer of the dermis, whereby the physiologically active agent is effused into the skin while staying in the upper layer of dermis. | 2009-09-17 |
20090232856 | STABLE THREE-PHASED EMULSIONS - Disclosed is a three-phase emulsion comprising an aqueous-gel outer phase; and a water-in-oil inner phase, wherein the emulsion is stable. The aqueous-gel outer phase can include 10% to 50% by weight of the total weight of the emulsion. This phase can also include 70% to 95% by weight of water based on the total weight of the aqueous-gel outer phase, a gelling agent, and an emulsifier having a hydrophilic-lipophilic balance (HLB) value of 10 to 19. The water-in-oil inner phase can include 50% to 95% by weight based on the total weight of the three-phase emulsion. This phase can also include 50% to 80% by weight of water based on the total weight of the water-in-oil inner phase, 20% to 50% by weight of oil based on the total weight of the water-in-oil inner phase, and an emulsifier. | 2009-09-17 |
20090232857 | METHOD AND PROCESS FOR THE PRODUCTION OF MULTI-COATED RECOGNITIVE AND RELEASING SYSTEMS - The present invention includes compositions, methods, systems for the controlled delivery of an active agent within a polymeric network upon the binding of a molecule that decreases the structural integrity of the polymeric network at one or more micro- or nanovacuoles. | 2009-09-17 |
20090232858 | METHOD AND PROCESS FOR THE PRODUCTION OF MULTI-COATED RECOGNITIVE AND RELEASING SYSTEMS - The present invention includes compositions, methods, systems for the controlled delivery of an active agent in a tablet polymer comprising two or more layers, wherein each of the two or more layers comprises at least one active agent and at least one molecular recognition polymer, wherein the two or more layers are compressed into a single tablet. | 2009-09-17 |
20090232859 | COSMETIC - A cosmetic, comprising a polymer (A) which comprises a repeating unit represented by the following formula (1), a repeating unit represented by the following formula (2) and a repeating unit represented by the following formula (3), said polymer (A) containing the repeating unit represented by the formula (3) in an amount of from 30 to 90 mass %, based on a total mass of the polymer (A), and being soluble in decamethylcyclopentasiloxane, | 2009-09-17 |
20090232860 | Colloidal metal-containing skin sanitizer - The present disclosure is drawn to disinfectant hand sanitizing compositions. In one embodiment, a hand sanitizing compositions can include from 10 to 1500 ppm colloidal silver, from 0.01 wt % to 30 wt % alcohol, at least 70 wt % water, and a thickening agent. The hand sanitizers can provide continued sanitization for an extended period of time and can be formulated to be dispensed as self-supporting foams. | 2009-09-17 |
20090232861 | EXTRACTION AND SEQUESTRATION OF CARBON DIOXIDE - The present disclosure provides a method and apparatus for extracting carbon dioxide (CO | 2009-09-17 |
20090232862 | Insect Screening Sheet - Described is an insect screening sheet having an insect-repellent layer ( | 2009-09-17 |
20090232863 | Biodegradable Carbon Diazeniumdiolate Based Nitric Oxide Donating Polymers - Disclosed herein are implantable medical devices coated with or comprising bioabsorbable carbon-based nitric oxide-donating polymers that upon exposure to physiological environments donate nitric oxide (NO). | 2009-09-17 |
20090232864 | METHOD FOR APPLYING A BIOACTIVE, TISSUE-COMPATIBLE LAYER ONTO SHAPED ARTICLES AND THE USE OF SUCH SHAPED ARTICLES - A method for applying a bioactive, tissue-compatible layer onto a shaped article includes providing, as a target material, a bioactive glass ceramic having a S53P4 composition, cleaning a shaped article and activating a surface of the shaped article with ions. The Shaped article is exposed to a bioactive glass ceramic beam pulse ablated by a pulsed electron-beam ablation of the bioactive glass ceramic target material so as to deposit a bioactive glass ceramic layer having a thickness ranging from 1 μm to 10 μm on the surface of the shaped article. A respective pulse frequency of the at least one of: 1) an electron pulse of the pulse electron beam abalation, and 2) the bioactive glass ceramic beam pulse, is controlled. Prior to an implantation, so as to avoid an initial cytotoxicity, at least one of the following is performed: a) an exposure of the article at least the times to | 2009-09-17 |
20090232865 | End-Capped Poly(Ester Amide) Copolymers - This invention relates to poly(ester amide)s (PEAs) comprising inactivated terminal amino and carboxyl groups, methods of synthesizing the inactivated PEAs and uses for them in the treatment of vascular diseases. | 2009-09-17 |
20090232866 | Oligopeptides as coating material for medical products - The present invention relates to a pharmaceutical composition comprising a caspase inhibitor and/or a compound of the general formula R-Lys-X, methods for coating medical products using said caspase inhibitors and/or said compounds of general formula R-Lys-X and medical products coated with said caspase inhibitors and/or said compounds of general formula R-Lys-X. | 2009-09-17 |
20090232867 | Modified conductive surfaces having active substances attached thereto - Novel processes for coating metal surfaces and/or for attaching active substances to metal surfaces, objects having coated metal surfaces and/or active substances attached thereto and uses thereof in the preparation of implantable devices are disclosed. | 2009-09-17 |
20090232868 | Nitric Oxide Releasing Polymer Composition - Disclosed herein are biocompatible carbon-based nitric oxide (NO) donating polymers suitable for forming and coating medical devices. These polymers have acrylate backbones and are comprised of substantially hydrophobic monomers. The NO donating polymers are carbon based wherein the diazeniumdiolate group is attached to the acetate group on an acetate based monomer. Incorporating a vinyl acetate monomer into an acrylate based polymer allows diazeniumdiolation of a polymer that would otherwise not accommodate the diazeniumdiolate group. | 2009-09-17 |
20090232869 | Filamentous Embolization Device With Expansible Elements - An embolization device for occluding a body cavity includes one or more elongated, expansible, hydrophilic embolizing elements non-releasably carried along the length of an elongated filamentous carrier that is preferably made of a very thin, highly flexible filament or microcoil of nickel/titanium alloy. At least one expansile embolizing element is non-releasably attached to the carrier. A first embodiment includes a plurality of embolizing elements fixed to the carrier at spaced-apart intervals along its length. In second, third and fourth embodiments, an elongate, continuous, coaxial embolizing element is non-releasably fixed to the exterior surface of the carrier, extending along a substantial portion of the length of the carrier proximally from a distal tip, and optionally includes a lumenal reservoir for delivery of therapeutic agents. Exemplary methods for making these devices include skewering and molding the embolizing elements. In any of the embodiments, the embolizing elements may be made of a hydrophilic, macroporous, polymeric, hydrogel foam material. In the second, third and fourth embodiments, the elongate embolizing element is preferably made of a porous, environmentally-sensitive, expansile hydrogel, which can optionally be made biodegradable and/or bioresorbable, having a rate of expansion that changes in response to a change in an environmental parameter, such as the pH or temperature of the environment. | 2009-09-17 |
20090232870 | APPARATUS AND METHOD OF RETAINING AND RELEASING MOLECULES FROM NANOSTRUCTURES BY AN EXTERNAL STIMULUS - An apparatus and method for using nanostructures, such as nanopores, nanofibers, nanowells, or nanocones as carriers for drugs, biomarkers and/or biomolecules. The apparatus and method for use on implant surfaces to retain and release drugs, biomarkers and/or biomolecules on command by an external stimulus. | 2009-09-17 |
20090232871 | Biocompatible polymers and co-polymers, and uses thereof - The invention relates to highly biocompatible or biophilic un-cross-linked or cross-linked polymers comprising one or more side-chain active acrylic amino acids of formula I | 2009-09-17 |
20090232872 | METHOD AND APPARATUS FOR MINIMIZING HEAT, MOISTURE, AND SHEAR DAMAGE TO MEDICANTS AND OTHER COMPOSITIONS DURING INCORPORATION OF SAME WITH EDIBLE FILMS - A medicant composition is provided. The composition includes a film layer and a powder matrix layer. The powder matrix layer includes a medicant. The powder matrix layer is applied to the film layer by admixing particulate to form a powder matrix and by then applying the powder matrix to the film layer by any desired method. The composition of the powder matrix is varied to alter the dissolution rate of the medicant, the adhesion of the medicant composition, and other physical properties of the powder matrix. The powder matrix layer can be cured. | 2009-09-17 |
20090232873 | Personal Care Composition in the Form of an Article - Personal care compositions, especially those personal care compositions in the form of an article that is a porous, dissolvable solid structure. | 2009-09-17 |
20090232874 | FIBROUS MEMBRANE FOR BIOMEDICAL APPLICATION BASED ON POLY(ESTER-AMIDE)S - Electrospun biodegradable poly(ester-amide) fabric is especially suitable as a scaffold for tissue engineering and to incorporate drug for burn or wound healing treatment to accelerate healing, or to prevent tissue adhesion after surgery. | 2009-09-17 |
20090232875 | CARTILAGINIFORM AND OSTEOCHONDRAL SUBSTITUTE COMPRISING A MULTILAYER STRUCTURE AND USE THEREOF - The present invention relates to a multilayer structure ( | 2009-09-17 |
20090232876 | Method and composition for in situ formation of an artificial blockage to control bleeding - A composition for in situ formation of an artificial blockage to control bleeding includes a suitable amount of a polymer-forming component, a suitable amount of a crosslinking agent, hydrogen peroxide, and a decomposing agent for hydrogen peroxide. The decomposing agent includes exogenous or endogenous catalase, or both. | 2009-09-17 |
20090232877 | Method and composition for in situ formation and/or expansion of a polymer-based hemostatic agent to control bleeding - A composition for in situ formation and/or expansion of a polymer-based hemostatic agent to control bleeding includes a suitable amount of a polymer or polymer-forming component, hydrogen peroxide or chemical(s) capable of forming hydrogen peroxide, or a combination of both, and a decomposing agent for hydrogen peroxide. The decomposing agent includes an endogenously or exogenously supplied catalyst (other than catalase), or both, and/or the polymer or polymer-forming component. | 2009-09-17 |
20090232878 | Artificial Skin Substitute - An improved skin substitute is presented comprised of non-biological materials produced with a series of regularly-spaced pores and a nylon weave netting. The top component is a thin (approximately 0.001″ thick) silicone elastomer in which pore holes have been vacuum-pulled; physically attached to the silicone elastomer is a fine knitted nylon fabric (12/1, 15/1 denier); incorporated into the silicone/nylon structure are collagen peptides [about 10 micrograms per square centimeter of Porcine type 1—“the active component”] without cross-linking agent to enable a quick interaction with fibrin in the wound to achieve acute adherence. | 2009-09-17 |
20090232879 | Thyromimetics for the Treatment of Fatty Liver Diseases - The present invention is directed toward the use of thyromimetic compounds that are thyroid receptor ligands, pharmaceutically acceptable salts thereof, and to prodrugs of these compounds for preventing, treating, or ameliorating fatty liver diseases such as steatosis, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis. | 2009-09-17 |
20090232880 | Analogue Compounds Of Archaebacterial Membrane Lipids And Liposomal Compounds Integrating Such Compounds - The invention relates to a compound of general formula (I): where =0 or 1, Z=O, S or CH | 2009-09-17 |
20090232881 | Enhanced Delivery of Skin Benefit Agents - Pro-vesicles for enhanced delivery of skin benefit agents through formation of vesicular phases in the presence of water in topically applied cosmetic products, said pro-vesicles comprising: (i) the benefit agent to be delivered; (ii) a phospholipid; (iii) a mono-, di- or tri-ester of glycerol; (iv) a straight or branched chain propyl or butyl ester of C | 2009-09-17 |
20090232882 | PEPTIDE BASED INHIBITION OF caPCNA INTERACTION IN CANCER - Peptides derived from cancer specific isoform of proliferating cell nuclear antigen (caPCNA, also known as csPCNA) or from nmPCNA-interacting proteins interfere with intracellular protein-protein interaction, thereby causing a reduction in the proliferative potential of cancer. These peptides serve as therapeutic compositions to reduce the proliferation of cancer cells and also augment existing chemotherapeutic methods. | 2009-09-17 |
20090232883 | METHOD OF SEPARATING VESICLE, PROCESS FOR PRODUCING MEDICINAL PREPARATION, AND METHOD OF EVALUATION - A method of separating vesicles whose membrane has been modified with a hydrophilic polymer (polyethylene glycol, etc.). In the method, vesicles (liposome, etc.) differing in the degree of membrane modification are separated by ion-exchange chromatography using a concentration gradient in which the ionic intensity of an eluent is changed with time. Also provided are: a process for producing vesicles purified so as to have a desired degree of modification with a hydrophilic polymer which comprises utilizing the separation method in the step of purifying vesicles; a method of evaluating a medicinal vesicle preparation containing a drug therein, the method comprising using the separation method; and vesicles in which the membrane has been modified with a hydrophilic polymer and which include no vesicle having a degree of membrane modification less than 0.5 mol %. | 2009-09-17 |
20090232884 | Composition and method for treatment of the side-effects associated with administration of cancer chemotherapeutic agents - A composition and method for the treatment of the side-effects associated with the administration of cancer chemotherapeutic agents involves the oral ingestion of cationic liposomes containing the substrates orotate, UMP and AMP. The cationic liposomes bind to the cells lining the mucosa of the intestinal tract and then the contents of the cationic liposome are then taken up in the interior of the cells to prevent the metabolism or anabolism of the cancer treatment drug 5-FU into a toxic species. | 2009-09-17 |
20090232885 | Drug Delivery Systems Comprising Weakly Basic Drugs and Organic Acids - The present invention is directed to pharmaceutical compositions, and methods of making such compositions, wherein the compositions comprise a plurality of TPR and RR particles, wherein: the TPR particles each comprise a core coated with a TPR layer; the core comprises a weakly basic, poorly soluble drug and a pharmaceutically acceptable organic acid separated from each other by an SR layer; the RR particles each comprise the weakly basic, poorly soluble drug, and release at least about 80 wt.% of the weakly basic, poorly soluble drug in about 5 minutes when dissolution tested using United States Pharmacopoeia (USP) dissolution methodology (Apparatus 2—paddles@ 50 RPM and a two-stage dissolution medium at 37° C., (first 2 hours in 0.1N HCl followed by testing in a buffer at pH 6.8). | 2009-09-17 |
20090232886 | ORAL DOSAGE COMBINATION PHARMACEUTICAL PACKAGING - Pharmaceutical fixed dose combination products are formed by merging a fixed dose of a first pharmaceutical formulation from primary module, with a fixed dose of a second pharmaceutical formulation from a secondary module In a preferred embodiment the first and second pharmaceutical formulations are separated from one another in a three piece capsule, a capsule-in-a-capsule or a tablet-in-a-capsule, and the primary and secondary modules are interchangeable. | 2009-09-17 |
20090232888 | SUSTAINED DELIVERY OF ANTIBIOTICS - The present invention is directed to compositions for the sustained delivery of an antibiotic, for example vancomycin, to achieve desirable release profiles. This application is also directed to methods of using the compositions and processes for manufacturing the compositions. | 2009-09-17 |
20090232889 | CRYSTALLINE SALTS OF QUINOLINE COMPOUNDS AND METHODS FOR PREPARING THEM - A stable solid pharmaceutical composition consisting essentially of an effective amount of a crystalline salt of formula (II) | 2009-09-17 |
20090232890 | COMPOSITIONS AND METHODS FOR DISTRACTION OSTEOGENESIS - The present invention relates to compositions and methods for use in osteodistraction procedures. In one embodiment, a method of stimulating osteogenesis during and/or following bone distraction comprises providing a composition comprising a PDGF solution disposed in a biocompatible matrix and applying the composition to at least one site of bone distraction. | 2009-09-17 |
20090232891 | Cell Transport Compositions and Uses Thereof - Compositions and methods have been developed for transporting compounds across membranes with little or no toxicity and, when targeted through the appropriate routes of administration (i.e., lung, gastrointestinal (GI) tract), little or no immune stimulation. The compositions can mediate cellular delivery of compounds that would otherwise not enter cells and enhance the intracellular delivery of compounds that would otherwise enter cells inefficiently. The methods are carried out by contacting a proximal face of a lipid bilayer or membrane (e.g. the surface of an intact cell) with a complex containing a compound (e.g., a therapeutic agent) and a diketopiperazine (DKP). DKP and the compound are non-covalently associated with each other or covalently bound to each other. | 2009-09-17 |
20090232892 | Cellooligosaccharide-Containing Composition - Disclosed is a cellooligosaccharide composition comprising, as the main ingredient, at least one cellooligosaccharide selected from the group consisting of cellobiose, cellotriose, cellotetraose, cellopentaose and cellohexaose, which is in the powdery form having an average L/D value of 3.0 or lower, a bulk density of 0.80 g/mL or lower and an angle of repose of 60° or lower. | 2009-09-17 |
20090232893 | miR-143 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION - The present invention concerns methods and compositions for identifying genes or genetic pathways modulated by miR-143, using miR-143 to modulate a gene or gene pathway, using this profile in assessing the condition of a patient and/or treating the patient with an appropriate miRNA. | 2009-09-17 |
20090232894 | Process for Stabilizing an Adjuvant Containing Vaccine Composition - The present invention relates to a process for stabilizing an adjuvant containing vaccine composition, an adjuvanted vaccine composition in dry form and in particular a process for stabilizing an influenza vaccine composition, particularly an adjuvanted influenza vaccine composition in dry form. | 2009-09-17 |
20090232895 | PROCEDURE AND DEVICES FOR THE CONTROLLED OBTAINING OF DRY SALINE AEROSOLS WITH THERAPEUTIC EFFECT - The patent refers to a procedure and devices for the generation of dry aerosols, continuously, by mechanic self-erosion, by average stirring in air or air-oxygen feed, of some crystals with special structure obtained by controlled crystallization processes. There can be also used other salts known to have physiological effects or mixtures of saline crystals with capacities close to the micro-particle generation. The devices can be for human or veterinary individual use, in intensive therapies or for producing aerosols with therapeutic or preventive effect in public rooms. | 2009-09-17 |
20090232896 | Use of Magnesium Stearate Dihydrate for Lubrication of Solid Pharmaceutical Compositions - The invention provides lubricant compositions comprising magnesium stearate dihydrate. The lubricant compositions may be used to lubricate a variety of bioactive formulations including pharmaceutical compositions. | 2009-09-17 |
20090232897 | PHARMACEUTICAL COMPOSITIONS COMPRISING CONJUGATED ESTROGENS - Pre-mix compositions containing conjugated estrogens and a pharmaceutical carrier, and pharmaceutical formulations containing a pre-mix composition. Further, the invention includes processes for preparing the premix compositions and pharmaceutical formulations containing pre-mix compositions. | 2009-09-17 |
20090232898 | Pharmaceutical Compositions Useful in the Treatment of Migraine - There is provided pharmaceutical compositions for the treatment of migraine comprising a pharmacologically-effective amount of a triptan or an ergot, or a pharmaceutically-acceptable salt thereof; a pharmacologically-effective amount of an antiemetic compound, or a pharmaceutically-acceptable salt thereof; a bioadhesion and/or a mucoadhesion promoting agent; and carrier particles, wherein the active ingredients are presented in particulate form upon the surfaces of the carrier particles, which carrier particles are larger in size than the particles of the active ingredients; and the bioadhesion and/or mucoadhesion promoting agent is, at least in part, presented on the surfaces of the carrier particles. | 2009-09-17 |
20090232899 | Mucoadhesive nanocomposite delivery system - A nanocomposite delivery system uses chitosan as a mucoadhesive material encapsulated in a surface modified network of colloidal nanoporous nanoparticles, such as silica, or other colloid-forming materials, especially metal oxides. Drug delivery systems may be provided by binding a drug to the chitosan/silica nanocomposite, typically by adding a drug or other active agent during in-situ gellation of colloidal silica. When the active agent is, for example, amoxicillin or other antibiotic agent, the drug delivery system may be used in the treatment of stomach ulcers, for example. | 2009-09-17 |
20090232900 | NANO-MICELLAR PREPARATION OF ANTHRACYLCLINE ANTITUMOR ANTIBIOTICS ENCAPSULATED BY THE PHOSPHATIDE DERIVATIZED WITH POLYETHYLENE GLYCOL - The present invention provides a nano-micellar preparation of anthracycline antitumor antibiotics for intravenous injection, which comprises a therapeutically effective amount of anthracycline antitumor antibiotics, a phosphatide derivatized with polyethylene glycol, together with pharmaceutically acceptable adjuvants. The preparation is prepared by encapsulating the medicament with a nano-micelle to obtain the nano-micellar preparation of anthracycline antitumor antibiotics for injection. The anthracycline antitumor antibiotics and the phosphatide derivatized with polyethylene glycol form a nano-micelle with a highly homogeneous particle size. In the micelle, the hydrophobic core of encapsulated medicament is surrounded by polyethylene glycol molecules to form a hydrophilic protective layer, so that the medicament is prevented from contacting with the enzymes and other protein molecules in blood and being recognized and phagocytozed by reticuloendothelial system in the body, and the circulation time in vivo of the micelle is prolonged. | 2009-09-17 |
20090232901 | POLYMERIC MICROSPHERES - The invention features core-shell microsphere compositions, hollow polymeric microspheres, and methods for making the microspheres. The microspheres are characterized as having a polymeric shell with consistent shell thickness. | 2009-09-17 |
20090232902 | NANOMETER MESOPOROUS SILICA-BASED XEROGEL STYPTIC MATERIAL AND ITS PREPARING PROCESS AND APPLICATION - The invention disclosed a novel mesoporous silica-based xerogel and its use in hemorrhage control. The mesoporous silica-based xerogel material has tunable mesopores (1-50 nm), high specific surface area (100-1400 m | 2009-09-17 |
20090232903 | BIOCIDE COMPOSITIONS - Compositions and methods that yield chlorine dioxide upon mixing with an aqueous solution. | 2009-09-17 |
20090232904 | Homeopathic Skin Care Compositions and Uses Thereof - The subject invention provides unique and advantageous compositions containing Argentum metallicum (homeopathic silver) for use in topical skin care. In one embodiment, the subject invention provides a gel formulation having an advantageous silver hydrosol component in addition to Argentum metallicum. In preferred embodiments of the composition of the subject invention, the formulation further comprises carbopol. Sodium hydroxide can be used as described herein to adjust the pH. | 2009-09-17 |
20090232905 | ESSENTIAL OILS BASED CLEANING AND DISINFECTING COMPOSITIONS - Cleaning and disinfecting compositions for cleaning, disinfecting and sanitizing inanimate and animate surfaces are provided. The cleaning and disinfecting compositions contain thyme oil or thyme oil and | 2009-09-17 |
20090232906 | Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions - The present invention discloses and claims: (i) compositions, methods, and kits which lead to an increase in patient survival time in cancer patients receiving chemotherapy; (ii) compositions and methods which cause cytotoxic or apoptotic potentiation of the anti-cancer activity of chemotherapeutic agents; (iii) compositions and methods for maintaining or stimulating hematological function in patients in need thereof, including those patients suffering from cancer; (iv) compositions and methods for maintaining or stimulating erythropoietin function or synthesis in patients in need thereof, including those patients suffering from cancer; (v) compositions and methods for mitigating or preventing anemia in patients in need thereof, including those patients suffering from cancer; (vi) compositions and methods for maintaining or stimulating pluripotent, multipotent, and unipotent normal stem cell function or synthesis in patients in need thereof, including those patients suffering from cancer; (vii) compositions and methods which promote the arrest or retardation of tumor progression in those cancer patients receiving chemotherapy; (viii) compositions and methods for increasing patient survival and/or delaying tumor progression while maintaining or improving the quality of life in a cancer patient receiving chemotherapy; (ix) novel methods of the administration of taxane and/or platinum medicaments and a Formula (I) compound of the present invention to a cancer patient; and (x) kits to achieve one or more of the aforementioned physiological effects in a patient in need thereof, including those patients suffering from cancer. | 2009-09-17 |
20090232907 | Compositions and methods for treatment of esophageal cancer - Novel ureyl-substituted naphthalimide derivatives, pharmaceutically acceptable salts thereof and solvates thereof, are useful for making pharmaceutical compositions for the treatment of cell proliferative diseases such as cancer. The invention also provides methods of treating specific types of cancer such as prostate, esophageal, glioblastoma, gliosarcoma, NSCLC, head and neck, and breast with the compounds described herein alone and in combination with antineoplastic agents. | 2009-09-17 |
20090232908 | STABLE AQUEOUS SOLUTION CONTAINING SODIUM PYRUVATE, AND THE PREPARATION AND USE THEREOF - A stable aqueous solution of sodium pyruvate for medical use, which contains mM sodium pyruvate and a stabilizer of sodium pyruvate, wherein the said stabilizer is H | 2009-09-17 |
20090232909 | Method for determining physiological effects of hemoglobin - NO preferentially binds to the minor population of the hemoglobin's vacant hemes in a cooperative manner, nitrosylates hemoglobin thiols, or reacts with liberated superoxide in solution. The distribution of minor forms of hemoglobin can be tested and the results can be used to predict whether a composition of hemoglobin will scavenge, load, eliminate, or donate NO. Hemoglobin thus serves to regulate the chemistry of NO. SNO-hemoglobin transfers NO equivalents to the red blood cell anion transport protein AE1, which serves to export NO from red blood cells. Regulation of AE1 function is the basis for methods of therapy to affect levels of NO or its biological equivalent. | 2009-09-17 |
20090232910 | Biomarkers and therapeutics targets for cognitive decline - Enrichment of S and Z polymorphisms of alpha-1-antitrypsin (AAT) in distinct subsets of patients with cognitive disorder (pre-existing affective disorders and APOE2 allele carriers) suggests that AAT variants are potential endophenotypes for Alzheimer Disease and related disorders of cognition, behavior and affect. Such disorders include ADD/ADHD, learning disabilities, ADEM, and susceptibility to brain injury in toxic/chemical/biological/immunological events. In Alzheimer Disease, S and Z alleles affect age of onset and low AAT levels define faster progression rate. Twenty to thirty percent of all dementia patients display AAT and/or We polymorphisms. Effects of AAT may involve inflammation of liver/lung, macrophage activation and iron and lipid metabolism. AAT, its regulation, and iron metabolism represent therapeutic targets and AAT can serve as a biomarker for vulnerability and disease progression. | 2009-09-17 |
20090232911 | Use of sericin for improving feeling in use of denture - The purpose is to prevent, ameliorate or relieve various conditions induced in the dried oral cavity or to improve the stability of a denture during use. A solution for treating a denture or a denture stabilizer comprising sericin can be used. | 2009-09-17 |
20090232912 | Method For Preparing Extract For The Prevention and Treatment Of Hyperlipidemia and Obesity From the Extract of Aster Spathulifolius Aerial Part and Composition Containing The Same - The present invention relates to a method for preparing an extract of the aerial part of | 2009-09-17 |
20090232913 | Composition for the Control of Cholesterol Levels - The present invention relates to a composition used to control cholesterol levels. In particular, the present invention relates to a method for the treatment or prevention of disorders or diseases mediated by hyperlipidemia, said method comprising administering to a mammalian subject in need thereof an effective amount of a composition comprising an extract from at least one plant from the genus | 2009-09-17 |
20090232914 | PHARMACEUTICAL COMPOSITION FOR TREATING DEPRESSION AND METHOD FOR PREPARATION THEREOF - A pharmaceutical composition for treating depression and method for preparation thereof is provided. The pharmaceutical composition includes Radix Ginseng, Radix Glycyrrhizae, and/or their aqueous or alcoholic extract. Fructus Jujubae or their aqueous or alcoholic extract can also be included in the pharmaceutical composition. | 2009-09-17 |
20090232915 | MIXTURES WITH A COLLAGEN SYNTHESIS BOOSTING ACTION - The invention relates to synergistically active, ternary mixtures which boost collagen synthesis and to the uses thereof, in particular for slowing down skin ageing and for wound healing of damaged skin. The invention furthermore relates to the use of the ternary mixtures according to the invention for treating the oral cavity and pharynx, and in particular therein for preventing and slowing down periodontitis, for building up periodontal connective tissue and for preventing and treating infections in the oral cavity and for wound healing in the oral cavity. | 2009-09-17 |
20090232916 | FOOD PRODUCTS FOR DIABETICS - Disclosed is a novel food product characterized by a low glucose or glucose free content, a balanced functional fat content, and a proactive agent aimed for the diabetic and diabetic-prone populations. The food product of the invention is a functional food which may be used clinically to lower the lipid level in people suffering from an imbalanced lipid profile and which may progress towards diabetes complications and coronary vascular disorders. In particular embodiments the proactive agent can be any of a naturally occurring lipid, a synthetic or mimetic lipid which is not digestible by humans and interferes with body weight gain/loss, plant extracts and substances derived therefrom, antioxidants, animal-derived substances, minerals and pharmaceuticals, and any mixture thereof. | 2009-09-17 |
20090232917 | COMPOSITION FOR RELIEVING SUBJECTIVE SYMPTOMS OF FATIGUE - There has been a demand in the marketplace for medicines, functional foods and so on which can relieve subjective symptoms of fatigue in persons having these subjective symptoms, and enabling the persons to have productive days. That is, an object of the present invention is to provide a composition for relieving subjective symptoms of fatigue. According to the present invention, a safe and effective composition for relieving subjective symptoms of fatigue which contains ornithine or a salt thereof as an active ingredient can be provided. | 2009-09-17 |
20090232918 | COMPOSITIONS AND METHODS FOR CONTROLLING INSECTS - The present invention comprises compositions, methods and cell lines related to controlling insects. An embodiment of a composition comprises a plant essential oil and targets at least one receptor of insects chosen from tyramine receptor, Or83b olfactory receptor, and Or43a olfactory receptor, resulting in a change in the intracellular levels of cAMP, Ca2+, or both in the insects. | 2009-09-17 |
20090232919 | Composition Comprising Liquiritigenin for Preventing and Treating Liver Disease - The present invention is related to a composition comprising an extract of licorice or liquiritigenin isolated therefrom significantly decrease the blood concentration of LDH and ALT enzyme, central necrosis and inflammation in acetaminophen-induced hepato-toxicity animal model when the inventive extract or compound of the present invention was orally and intravenously administrated thereto. Accordingly, the inventive compositions according to the present invention are useful in the prevention and treatment of the liver diseases and can be used as safe and efficient hepato-protective | 2009-09-17 |
20090232920 | SUPERFINE FIBER CREATING SPINNERET AND USES THEREOF - Apparatuses and methods for the production of superfine fibers. | 2009-09-17 |
20090232921 | IMPACT TARGET CAPSULE AND IMPACT COMPRESSION APPARATUS - A target capsule includes (A) a pedestal having a central projection, (B) a pedestal aid attached to the central projection so as to define a sample-loading assembly, and (C) an impact-receiving member, wherein the components (A), (B), and (C) are detachable from each other. The impact target capsule can be readily loaded with a sample, allows the sample to be easily retrieved after application of impact pressure, and can be used repeatedly, and thereby the capsule can be preferably used as an impact compression apparatus in combination with a single-stage powder gun or a single-stage gas gun. | 2009-09-17 |
20090232922 | DEVICE FOR FILLING AT LEAST ONE DOSING CHAMBER - A device for filling at least one dosing chamber is provided, with at least one dosing chamber arranged in a dosing disc into which a filling material is to be introduced. At least one ram acts on the material located in the dosing chamber. The at least one ram is arranged on a support, and at least two columns are connected to the support. A drive mechanism is provided which, via a coupling mechanism, moves at least the two columns up and down in synch. | 2009-09-17 |
20090232923 | ADJUSTABLE CLAMPING TABLE FOR THERMOFORMING MACHINES - An adjustable clamping table for a molding station of a thermoforming machine. The clamping table includes a stationary base plate defining a rectangular opening of a window having crosswise and longitudinally extending sides; a pair of upper and a pair of lower movable plates sliding supported by the stationary plate, at right-angled directions; to each clamping bars along internal edges of the sliding plates, the sliding plates having longitudinal edges defining an upper resting surface for supporting and locking a sheet of thermoformable plastic material, a resting and sealing bottom surface for a thermoforming mold. The clamping bars of lower cross plates being telescopically adjustable and supported by respective metal sheets which extend from the internal edge of the same cross plates. | 2009-09-17 |
20090232924 | SHAPE-FORMING SHUTTER APPARATUS AND SHUTTER PIECE THEREOF - Disclosed is an shape-forming shutter apparatus including a plurality of shutter pieces, each having an shaping surface and a sliding surface, which are arranged in a circle with the shaping surface of each shutter piece being slidably in sliding contact with the sliding surface of the neighboring separate shutter piece, and the shape-forming shutter apparatus being capable of dilating and contracting an opening part surrounded by the shaping surfaces respectively of the plurality of shutter pieces. The shape-forming shutter apparatus includes pressure contact biasing means for always keeping the shaping surface of each shutter piece and the sliding surface of the neighboring shutter piece slidably in pressure contact with each other. The pressure contact biasing means is a ring-shaped elastic member for biasing the shutter pieces equally in such a direction to close the opening part. The elastic member is stretchingly wound around the shutter pieces in an end of each shutter piece, which end is separate away from the other end thereof where the shaping surface of the shutter piece and the sliding surface of the neighboring shutter piece intersect each other. | 2009-09-17 |
20090232925 | CUTTING MOLD FOR RIGID-FLEXIBLE CIRCUIT BOARD AND METHOD FOR FORMING THE SAME - A cutting mold for removing two opposite superfluous rigid circuit boards from a rigid-flexible circuit board. A first cutter is connected to a first moldboard. A first barricade is connected to the first moldboard. The maximum vertical distance from the first barricade to the first moldboard exceeds that from the first cutter to the first moldboard. A second moldboard is opposite the first moldboard. The first and second moldboards move with respect to each other. A second cutter is connected to the second moldboard and corresponds to the first cutter. A second barricade is connected to the second moldboard and detachably abuts the first barricade. The maximum vertical distance from the second barricade to the second moldboard exceeds that from the second cutter to the second moldboard. The first and second cutters cut the superfluous rigid circuit boards when the first and second moldboards move toward each other. | 2009-09-17 |
20090232926 | SEGMENTED PRESSWARE DIE SET WITH ANTI-TWIST GUIDE KEYS - A heated, segmented pressware die set for making pressware containers from a paperboard blank includes a plurality of guide keys mounted between at least one of an inner member of a punch or die and an outer ring which reciprocates independently. Each guide key extends in an outward direction from the central axis of the die set. The guide keys are positioned, configured and dimensioned to engage the outer ring in order to limit rotation of the outer ring with respect to the inner member of the punch or die. In a preferred construction, the guide keys have radially extending planar surfaces which cooperate with guide channels having like surfaces such that clearances necessary to accommodate thermal expansion are reduced, greatly increasing durability of the tool. | 2009-09-17 |
20090232927 | HONEYCOMB STRUCTURE-FORMING DIE AND METHOD FOR MANUFACTURING THE SAME - A honeycomb structure-forming die 1 has a die substrate 22 including a first plate-shaped member 23 having back holes 6 for introducing a raw forming material and a second plate-shaped member 24 having slits 5 for forming the material into a lattice shape. The first plate-shaped member 23 has columnar portions 8 where at least a part is zoned by a slit-shaped groove portion 7 corresponding with a shape of the slit 5 on a bonding face side 28 where the first plate-shaped member 23 is bonded with the second plate-shaped member 24. In the columnar portions 8, the ratio (L/T) of the height L of the columnar portions 8 to the minimum width T in an end face on the bonding face side 28 is within 1/3 to 3.5. Thus constituted die realizes high formability, and two plate-shaped members constituting the die substrate are hardly peeled from each other. | 2009-09-17 |
20090232928 | Method of Manufacturing Stamper, and Stamper - According to one embodiment, a method of manufacturing a stamper includes forming a conductive layer on a surface of a master having patterns of protrusions and recesses, forming an electroforming layer on the conductive layer, separating the electroforming layer and the conductive layer from the master to form a stamper to which the patterns of protrusions and recesses of the master are transferred, removing a resist left on the surface of the stamper, and etching the surface of the stamper with an acidic solution having a pH value of less than 3. | 2009-09-17 |
20090232929 | Mould Housing - A mould housing ( | 2009-09-17 |
20090232930 | Disk Molding Mold, Mirror Surface Disk, and Method of Manufacturing Mirror Surface Disk - An object is to prevent a disk substrate from warping to thereby improve the quality of the disk substrate. A disk molding mold includes a first support plate; a first mirror surface disk attached to the first support plate; a second support plate; and a second mirror surface disk attached to the second support plate and facing the first mirror surface disk. At least one of the first and second mirror surface disks comprises a first plate, and a second plate disposed to surround at least a front surface of the first plate. The first plate comprises a temperature control flow passage ( | 2009-09-17 |
20090232931 | INJECTION NOZZLE FOR GUIDING HOT-MELT PLASTIC WITHIN A MOLD - Among other things, the invention relates to an injection nozzle for guiding hot-melt plastic within a mold, particularly an injection mold. Said injection nozzle comprises a nozzle housing ( | 2009-09-17 |
20090232932 | Syringe mold - A syringe mold with a coolant circulation outward and homeward positioned close to the cavity space and a sufficient coolant circulating flow for cooling a core cylinder is provided. | 2009-09-17 |
20090232933 | FEED ADDITIVE COMPOSITION FOR RUMINANTS AND METHOD OF PRODUCING THE SAME - A food additive composition for ruminants of the dispersion type and a method of continuously producing the same. This food additive composition for ruminants, which contains 40% by weight or more but less than 65% by weight of a basic amino acid and has rumen bypass properties, is formulated into granules in an arbitrary shape which are scarcely classified when added to a silage or another feed. Thus, attempts have been made to develop a method of producing granules by which the milk yield of a lactation cow can be increased. Namely, it is intended to provide a food additive composition for ruminants which contains at least one protecting agent selected from among a hardened vegetable oil and a hardened animal oil having a melting point higher than 50° C. but lower than 90° C., 0.05 to 6% by weight of lecithin, water and 40% by weight or more but less than 65% by weight of a basic amino acid. It is also intended to provide a method of producing a food additive composition for ruminants characterized by comprising solidifying a molten mixture, which comprises at least one protecting agent selected from among a hardened vegetable oil and a hardened animal oil having a melting point higher than 50° C. but lower than 90° C., lecithin and a basic amino acid, by dipping in water. | 2009-09-17 |